Literature DB >> 11126431

Potential interventions for HIV/AIDS wasting: an overview.

D I Abrams1.   

Abstract

Although the HIV wasting syndrome has become a far less common manifestation of advanced disease since the introduction of highly active therapies, much has been learned about a number of potential therapeutic interventions. HIV wasting therapies are reviewed. The evaluation of some of these treatments for management of body habitus alterations associated with antiretroviral therapies may be appropriate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11126431     DOI: 10.1097/00042560-200010001-00012

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  9 in total

1.  Δ9-Tetrahydrocannabinol Suppresses Secretion of IFNα by Plasmacytoid Dendritic Cells From Healthy and HIV-Infected Individuals.

Authors:  Joseph E Henriquez; Michael D Rizzo; Matthias A Schulz; Robert B Crawford; Peter Gulick; Norbert E Kaminski
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-15       Impact factor: 3.731

2.  Dronabinol and marijuana in HIV(+) marijuana smokers: acute effects on caloric intake and mood.

Authors:  Margaret Haney; Judith Rabkin; Erik Gunderson; Richard W Foltin
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

3.  Interferon-α-Mediated Activation of T Cells from Healthy and HIV-Infected Individuals Is Suppressed by Δ9-Tetrahydrocannabinol.

Authors:  Joseph E Henriquez; Michael D Rizzo; Robert B Crawford; Peter Gulick; Norbert E Kaminski
Journal:  J Pharmacol Exp Ther       Date:  2018-07-19       Impact factor: 4.030

4.  Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study.

Authors:  Gillinder Bedi; Richard W Foltin; Erik W Gunderson; Judith Rabkin; Carl L Hart; Sandra D Comer; Suzanne K Vosburg; Margaret Haney
Journal:  Psychopharmacology (Berl)       Date:  2010-09-08       Impact factor: 4.530

5.  Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus.

Authors:  Cecilia T Costiniuk; Edward Mills; Curtis L Cooper
Journal:  Can J Gastroenterol       Date:  2008-04       Impact factor: 3.522

Review 6.  Substance use in older HIV-infected patients.

Authors:  E Jennifer Edelman; Jeanette M Tetrault; David A Fiellin
Journal:  Curr Opin HIV AIDS       Date:  2014-07       Impact factor: 4.283

7.  HIV-infected cannabis users have lower circulating CD16+ monocytes and IFN-γ-inducible protein 10 levels compared with nonusing HIV patients.

Authors:  Michael D Rizzo; Robert B Crawford; Joseph E Henriquez; Yasser A Aldhamen; Peter Gulick; Andrea Amalfitano; Norbert E Kaminski
Journal:  AIDS       Date:  2018-02-20       Impact factor: 4.177

8.  Health-related quality of life in HIV-infected patients: the role of substance use.

Authors:  P Todd Korthuis; Laurie C Zephyrin; John A Fleishman; Somnath Saha; Joshua S Josephs; Moriah M McGrath; James Hellinger; Kelly A Gebo
Journal:  AIDS Patient Care STDS       Date:  2008-11       Impact factor: 5.078

9.  The frequency and magnitude of growth failure in a group of HIV-infected children in Cameroon.

Authors:  Andreas Chiabi; Jacqueline Lebela; Marie Kobela; Lawrence Mbuagbaw; Marie Thérèse Obama; Tetanye Ekoe
Journal:  Pan Afr Med J       Date:  2012-01-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.